Summary
Pfizer Inc. has announced a significant step towards the completion of its previously announced separation of its Upjohn business, which primarily consists of off-patent branded and generic established medicines. On October 30, 2020, the company issued a press release confirming the receipt of all necessary antitrust approvals. This clearance is a critical milestone, paving the way for the anticipated closing of the spin-off transaction. Following the spin-off, the Upjohn business is set to combine with Mylan N.V. This strategic move is designed to unlock value by creating two more focused companies: one centered on innovative medicines and the other on established medicines. Investors should monitor the official closing date for this transaction, as it will mark the formal separation of these distinct business segments and the formation of the new combined entity with Mylan.
Key Highlights
- 1Pfizer received all required antitrust approvals for the spin-off of its Upjohn business.
- 2The Upjohn business will be spun off and subsequently combined with Mylan N.V.
- 3This transaction represents a strategic move to create two more focused companies.
- 4The press release announcing these approvals was issued on October 30, 2020.
- 5Antitrust clearance is a key prerequisite for the transaction's closing.